Original Research
Accepted on 21 Jan 2026
Drug-Associated Insomnia and Sex-Specific Disproportionality in the FDA Adverse Event Reporting System (2019–Q1 2025)
in Pharmacoepidemiology
Frontiers in Pharmacology
- 173 views
Type at least 3 characters
601 articles
articles
Original Research
Accepted on 21 Jan 2026
Genetic Pharmacoepidemiology of JAK Inhibitors in Chronic Immune-Mediated Skin Diseases: Implications for Precision Therapy and Medication Safety
in Pharmacoepidemiology
Frontiers in Pharmacology
- 152 views
Original Research
Published on 21 Jan 2026
Real-world landscape of drug-related ocular injuries: a retrospective pharmacovigilance study
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2026.1731545
- 1,473 views
Original Research
Published on 16 Jan 2026
Tramadol use is associated with reduced 28-day mortality in ICU patients after cardiac surgery: a retrospective study based on the MIMIC-IV database
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2026.1770570
- 744 views
Original Research
Published on 14 Jan 2026
Beyond the label: real-world gastrointestinal adverse events associated with vedolizumab – a decade of FAERS pharmacovigilance
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1700820
- 739 views
Original Research
Published on 13 Jan 2026
Hemorrhagic risk of concomitant direct oral anticoagulants and fluoroquinolones: integration of pharmacovigilance and therapeutic drug monitoring
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2026.1745035
- 1,496 views
Original Research
Published on 13 Jan 2026
Real-world adverse event profile and signal characteristics of bevacizumab in glioma: a FAERS-based disproportionality analysis
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1705451
- 683 views
Original Research
Published on 12 Jan 2026
Prevalence and risk factors of burnout among community pharmacists in the Aseer region, Saudi Arabia: a cross-sectional study
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2026.1737667
- 607 views
Systematic Review
Published on 12 Jan 2026
Risk of neutropenia associated with Sacituzumab govitecan: a systematic review combined with the FAERS database and meta-analysis
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1714638
- 1,047 views
Original Research
Published on 12 Jan 2026
Association of medication regimen complexity index with ADRs in HIV/AIDS patients: a retrospective cohort study
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1721289
- 634 views
Original Research
Published on 12 Jan 2026
Psychotropic medication use and risks of kidney injury and fall-related events: a propensity score–matched cohort study
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1690792
- 860 views
Original Research
Published on 08 Jan 2026
Atrial fibrillation signals associated with overactive bladder drugs across JADER and FAERS: disproportionality and time-to-onset analyses
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1700587
- 1,645 views
Original Research
Published on 08 Jan 2026
Drug-induced peripheral nerve palsy: a real-world study based on FAERS data from 2004 to the third quarter of 2024
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1691263
- 814 views
Original Research
Published on 07 Jan 2026
Pharmacovigilance insights: safety profiles of antifungal agents for invasive aspergillosis
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1718019
- 858 views
Original Research
Published on 07 Jan 2026
Medication use in Poland for children and adolescents with neurodevelopmental disorders: before, during and after the COVID-19 pandemic - a retrospective pharmacoepidemiological study using national reimbursement data
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1728388
- 1,023 views
Original Research
Published on 07 Jan 2026
Comparative safety profiles of spironolactone, eplerenone, and finerenone: a pharmacovigilance study based on FAERS data from 2004 to 2024
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1702257
- 1,537 views
Original Research
Published on 05 Jan 2026
Voriconazole-associated liver injury: clinical risk factor identification and predictive nomogram construction
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1688711
- 809 views
Original Research
Published on 05 Jan 2026
Maternal influenza vaccination during pregnancy and the risk of adverse pregnancy and birth outcomes
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1691111
- 883 views
Original Research
Published on 05 Jan 2026
Pharmacovigilance signal detection of psychiatric adverse events induced by third-generation antiepileptic drugs in children
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1711879
- 995 views
Original Research
Published on 05 Jan 2026
Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1712361
- 1,102 views
Original Research
Published on 02 Jan 2026
Spectrum mining of immune checkpoint inhibitor-related cutaneous toxicities and analysis of associated factors based on FAERS
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1684390
- 1,402 views
Original Research
Published on 19 Dec 2025
Hydroxyurea utilization among individuals with sickle cell disease in Tennessee: a pooled analysis of claims data
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1693126
- 1,195 views
Original Research
Published on 12 Dec 2025
Medication adherence in the elderly population with chronic diseases: a factor analysis
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1699999
- 1,479 views
Original Research
Published on 11 Dec 2025
Disproportionality analysis of safety signals for milnacipran and levomilnacipran: a pharmacovigilance study using the FDA adverse event reporting system
in Pharmacoepidemiology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1719881
- 1,344 views